
Cardiol Therapeutics Inc. (CRDL) Stock Ticker
CRDL right now
Market factors today
Unlock the full CRDL picture
About Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.
CRDL stock facts
| Ticker symbol | CRDL |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market cap | $197.1M |
| CEO | David G. Elsley |
| Employees | 18 |
| Headquarters | Oakville, ON, CA |
| IPO date | 2019-01-15 |
| Website | www.cardiolrx.com |
What you can see for CRDL on Tickr
Live CRDL price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the CRDL report.
Rankings
CRDL peers
FAQ
What is the ticker symbol for Cardiol Therapeutics Inc.?
The ticker symbol for Cardiol Therapeutics Inc. is CRDL, listed on the NASDAQ Capital Market.
What is CRDL?
Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a…